exelixis inc. - EXEL
EXEL
Close Chg Chg %
46.21 1.95 4.22%
Closed Market
48.16
+1.95 (4.22%)
Volume: 2.18M
Last Updated:
May 8, 2026, 4:00 PM EDT
Company Overview: exelixis inc. - EXEL
EXEL Key Data
| Open $46.57 | Day Range 46.46 - 48.17 |
| 52 Week Range 33.76 - 49.40 | Market Cap $11.62B |
| Shares Outstanding 251.36M | Public Float 242.64M |
| Beta 0.38 | Rev. Per Employee N/A |
| P/E Ratio 15.32 | EPS $3.13 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.77M |
EXEL Performance
| 1 Week | 5.79% | ||
| 1 Month | 4.38% | ||
| 3 Months | 5.26% | ||
| 1 Year | 27.76% | ||
| 5 Years | 84.03% |
EXEL Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
21
Full Ratings ➔
About exelixis inc. - EXEL
Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
EXEL At a Glance
Exelixis, Inc.
1851 Harbor Bay Parkway
Alameda, California 94502
| Phone | 1-650-837-7000 | Revenue | 2.32B | |
| Industry | Pharmaceuticals: Major | Net Income | 782.57M | |
| Sector | Health Technology | 2025 Sales Growth | 6.982% | |
| Fiscal Year-end | 12 / 2026 | Employees | 1,077 | |
| View SEC Filings |
EXEL Valuation
| P/E Current | 16.141 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 15.697 |
| Price to Sales Ratio | 5.294 |
| Price to Book Ratio | 5.293 |
| Price to Cash Flow Ratio | 13.89 |
| Enterprise Value to EBITDA | 12.395 |
| Enterprise Value to Sales | 4.924 |
| Total Debt to Enterprise Value | 0.018 |
EXEL Efficiency
| Revenue/Employee | 2,154,248.839 |
| Income Per Employee | 726,620.241 |
| Receivables Turnover | 7.751 |
| Total Asset Turnover | 0.791 |
EXEL Liquidity
| Current Ratio | 3.558 |
| Quick Ratio | 3.505 |
| Cash Ratio | 2.611 |
EXEL Profitability
| Gross Margin | 96.393 |
| Operating Margin | 38.476 |
| Pretax Margin | 40.567 |
| Net Margin | 33.73 |
| Return on Assets | 26.668 |
| Return on Equity | 35.527 |
| Return on Total Capital | 33.128 |
| Return on Invested Capital | 32.816 |
EXEL Capital Structure
| Total Debt to Total Equity | 9.296 |
| Total Debt to Total Capital | 8.505 |
| Total Debt to Total Assets | 6.971 |
| Long-Term Debt to Equity | 8.006 |
| Long-Term Debt to Total Capital | 7.325 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Exelixis Inc. - EXEL
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.61B | 1.83B | 2.17B | 2.32B | |
Sales Growth
| +12.27% | +13.60% | +18.49% | +6.98% | |
Cost of Goods Sold (COGS) incl D&A
| 57.91M | 72.55M | 76.22M | 83.70M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 20.88M | 25.72M | 28.80M | 29.05M | |
Depreciation
| 20.88M | 25.72M | 28.80M | 29.05M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +9.52% | +25.28% | +5.06% | +9.82% | |
Gross Income
| 1.55B | 1.76B | 2.09B | 2.24B | |
Gross Income Growth
| +12.38% | +13.17% | +19.05% | +6.88% | |
Gross Profit Margin
| +96.41% | +96.04% | +96.49% | +96.39% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.35B | 1.59B | 1.40B | 1.34B | |
Research & Development
| 891.81M | 1.04B | 910.41M | 825.00M | |
Other SG&A
| 459.86M | 542.71M | 492.13M | 518.73M | |
SGA Growth
| +23.39% | +17.39% | -11.61% | -4.19% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | (1.20M) | 85.33M | 20.51M | |
EBIT after Unusual Expense
| 202.68M | 170.88M | 604.62M | 872.19M | |
Non Operating Income/Expense
| 31.67M | 86.64M | 77.02M | 69.02M | |
Non-Operating Interest Income
| 33.06M | 86.54M | 77.16M | 69.21M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 234.35M | 257.52M | 681.64M | 941.21M | |
Pretax Income Growth
| -20.33% | +9.89% | +164.69% | +38.08% | |
Pretax Margin
| +14.55% | +14.07% | +31.43% | +40.57% | |
Income Tax
| 52.07M | 49.76M | 160.37M | 158.64M | |
Income Tax - Current - Domestic
| - | 182.97M | 219.83M | 32.40M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | (133.21M) | (59.46M) | 126.24M | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 182.28M | 207.76M | 521.27M | 782.57M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 182.28M | 207.76M | 521.27M | 782.57M | |
Net Income Growth
| -21.11% | +13.98% | +150.89% | +50.13% | |
Net Margin Growth
| +11.31% | +11.35% | +24.04% | +33.73% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 182.28M | 207.76M | 521.27M | 782.57M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 182.28M | 207.76M | 521.27M | 782.57M | |
EPS (Basic)
| 0.5669 | 0.653 | 1.7973 | 2.8817 | |
EPS (Basic) Growth
| -22.74% | +15.19% | +175.24% | +60.33% | |
Basic Shares Outstanding
| 321.53M | 318.15M | 290.03M | 271.57M | |
EPS (Diluted)
| 0.5616 | 0.6463 | 1.7602 | 2.7764 | |
EPS (Diluted) Growth
| -21.65% | +15.08% | +172.35% | +57.73% | |
Diluted Shares Outstanding
| 324.56M | 321.46M | 296.13M | 281.86M | |
EBITDA
| 222.36M | 196.60M | 718.75M | 921.76M | |
EBITDA Growth
| -25.95% | -11.58% | +265.59% | +28.24% | |
EBITDA Margin
| +13.80% | +10.74% | +33.14% | +39.73% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 47.529 | |
| Number of Ratings | 21 | Current Quarters Estimate | 0.839 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | 3.492 | |
| Last Quarter’s Earnings | 0.87 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 3.08 | Next Fiscal Year Estimate | 3.992 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 14 | 14 | 13 | 14 |
| Mean Estimate | 0.84 | 0.87 | 3.49 | 3.99 |
| High Estimates | 0.92 | 0.95 | 3.72 | 4.94 |
| Low Estimate | 0.70 | 0.74 | 3.14 | 2.99 |
| Coefficient of Variance | 7.18 | 8.08 | 5.76 | 13.89 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 10 | 10 | 10 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 10 | 10 | 11 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Exelixis Inc. - EXEL
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Exelixis Inc. - EXEL
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 20, 2026 | Julie Anne Smith Director | 63,012 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $18.19 per share | 1,146,188.28 |
| Feb 20, 2026 | Julie Anne Smith Director | 20,590 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $43.33 per share | 892,164.70 |
| Feb 20, 2026 | Julie Anne Smith Director | 64,677 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $19.39 per share | 1,254,087.03 |
| Feb 20, 2026 | Julie Anne Smith Director | 20,590 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $44.5 per share | 916,255.00 |
| Feb 20, 2026 | Julie Anne Smith Director | 40,620 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $21.69 per share | 881,047.80 |
| Feb 20, 2026 | Julie Anne Smith Director | 20,590 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $44.3 per share | 912,137.00 |
| Feb 20, 2026 | Julie Anne Smith Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Julie Anne Smith Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Julie Anne Smith Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |